 As part of this research study, the participant will take alisertib in combination with conventional chemotherapies, idarubicin and cytarabine. Alisertib has not been approved by the FDA U.S. Food and Drug Administration for acute myeloid leukemia AML. However, cytarabine and idarubicin have both been approved by the FDA for treatment of AML. It also means that the FDA U.S. Food and Drug Administration has not approved giving alisertib with idarubicin and cytarabine for use in participants, including participants with this type of cancer. 